Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment

Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment
Takeda Pharmaceutical Company has submitted a new drug application to Japanese regulators for vedolizumab (MLN0002) as a treatment for adults with moderate to severe ulcerative colitis. Ulcerative colitis “is a chronic, progressive inflammatory disease of the large intestine, which typically affects young adults,” Toshiro Heya, head of Takeda Development Center Japan, said in a press release. “The

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *